UnknownNCT06126263

Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections

Studying Bacterial toxic-shock syndrome

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institutes of Health Clinical Center (CC)
Principal Investigator: Ahmed Babiker
Emory University
Intervention: Linezolid(drug)
Enrollment: 1000 enrolled
Eligibility: 18-100 years · All sexes
Timeline: 2023 – 2024

Study locations (1)

National Institutes of Health Clinical Center (primary center conducting large database study), Bethesda, Maryland, United States

Collaborators

Emory University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06126263 on ClinicalTrials.gov

Other trials for Bacterial toxic-shock syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07199998
Impact of Internal Menstrual Protections on Immunity and Vaginal Microbiota
Centre National de la Recherche Scientifique, France

See all trials for Bacterial toxic-shock syndrome →

← Back to all trials